Doctors News Hubb
Advertisement Banner
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us
No Result
View All Result
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us
No Result
View All Result
Doctors News Hubb
No Result
View All Result
Home News

Checkpoint Immunotherapy Effectiveness in Advanced NSCLC Related with the 27-gene IO Score

admin by admin
March 31, 2023
in News


The following is a summary of the “27-gene Immuno-Oncology (IO) Score is Associated With Efficacy of Checkpoint Immunotherapy in Advanced NSCLC: A Retrospective BC Cancer Study,” published in the March 2023 issue of Lung Cancer by Saltman, et al.


In advanced non-small cell lung cancer, immunotherapy in the form of immune checkpoint inhibitors (ICI) is the gold standard NSCLC. Despite this, not all patients benefit, even among those with a PD-L1 tumor proportional score (TPS) 50%, highlighting the unmet need for additional biomarkers such as those assessing the tumor immune microenvironment (TIME). DetermaIO is a gene expression analysis that classifies TIME along 27 different genes and has been linked to ICI response.

Patients with a performance status (PS) of 2 or higher and who had received at least 2 cycles of ICI monotherapy in first (1L) or second (2L) line treatment at BC Cancer or West Clinic Cancer Center provided the FFPE samples (2L). The correlation between IO scores and PFS and OS was investigated. Overall survival (HR=0.68, 95%CI 0.47-0.99, P =.042) and progression-free survival (HR=0.62, 95%CI 0.43-0.88, P =.0069) were both significantly correlated with IO score in the entire cohort (N=147). 

The IO score was significantly associated with PFS (HR=0.55, 95% CI 0.32-0.94, P =.028) in patients who were treated with 1L (PD-L150%, N=78). It was confirmed in PFS subgroup analysis in the independent West Cancer Center study (N=13 HR=0.14, 95%CI 0.027-0.76, P =.023) that IO score was associated with benefit in 1L PS2 patients for OS (HR = 0.26, 95%CI 0.091-0.74, P =.012) and PFS (HR = 0.27, 95%CI 0.098-0.72, P =.0095). These results corroborate the prior observation that DetermaIO is associated with ICI clinical benefit in NSCLC and extend previous research by showing that PD-L150% patients treated in the first line can be further stratified by IO score to identify efficacy. Initial hypothesis testing indicated that the IO score can identify benefit in patients with low PS.

Source: sciencedirect.com/science/article/pii/S1525730422002686



Source link

Advertisement Banner
Previous Post

Integrative Medicine Relies on Trust, Collaboration to Succeed

Next Post

Can American Democracy Pass The Trump Stress Test? – The Health Care Blog

Related Posts

News

Changes in Regional Brain Volume and Professional Fighters Cognition with TES

September 21, 2023
News

Infographic Participatory Design to Support the Care of Complex Regional Pain Syndrome

September 20, 2023
News

Correlation Between WWI and Chronic Kidney Disease

September 19, 2023
News

Community-Engaged QI For Medical Students Through Action Projects

September 18, 2023
News

Antidepressants are effective in patients with comorbid depression and medical diseases

September 17, 2023
News

#VisualAbstract: Prehospital Tranexamic Acid for Severe Trauma

September 16, 2023
Next Post

Can American Democracy Pass The Trump Stress Test? – The Health Care Blog

Recommended

Analyzing if ‘Knee’ Pattern in Spirometry Flow-Volume Curves in Children is Related to Tracheomalacia

10 months ago

The Dos and Dont’s of Difficult Airways

3 months ago

Top 2023 policy stories: end of public health emergency and telehealth

6 months ago

Freelancers: AHCJ’s 36 market guides can help you craft your pitches

9 months ago

Lower Face, Jawline, and Neck Radiofrequency Microneedling

9 months ago

© Doctors News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us

Newsletter Sign Up.

No Result
View All Result
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us

© 2022 Doctors News Hubb All rights reserved.